Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
3.295
-0.005 (-0.15%)
May 9, 2025, 11:21 AM - Market open
Arbutus Biopharma Employees
Arbutus Biopharma had 44 employees as of December 31, 2024. The number of employees decreased by 29 or -39.73% compared to the previous year.
Employees
44
Change (1Y)
-29
Growth (1Y)
-39.73%
Revenue / Employee
$140,250
Profits / Employee
-$1,589,091
Market Cap
630.93M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
Eli Lilly and Company | 47,000 |
ABUS News
- 2 days ago - Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025 - GlobeNewsWire
- 16 days ago - Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 - GlobeNewsWire
- 6 weeks ago - Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle - Market Watch
- 6 weeks ago - Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna - GlobeNewsWire
- 2 months ago - Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO - GlobeNewsWire
- 3 months ago - Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr. - Seeking Alpha
- 4 months ago - Arbutus Provides 2025 Corporate and Financial Update - GlobeNewsWire